Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Erlotinib vs Erlotinib in Advanced NSCLC
NCT00100854Phase 2Completed
- Sponsor
- TRIO
- Start
- Oct 2004
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in non-small cell lung cancer (NSCLC) (2 arms), sponsored by TRIO. Primary endpoint: Objective Tumor Response at 30 days. Started Oct 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00100854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100854.